Differential expression of the Notch1 receptor, and its ligands Dll1, Dll3 and Dll4 in distinct human pituitary adenoma subtypes

Zhang,Jianfu; Gao,Hua; Zhang,Yazhuo

doi:10.3892/ol.2017.5997

Differential expression of the Notch1 receptor, and its ligands Dll1, Dll3 and Dll4 in distinct human pituitary adenoma subtypes

Authors:
- Jianfu Zhang
- Hua Gao
- Yazhuo Zhang
View Affiliations

Affiliations: Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, P.R. China
Published online on: April 5, 2017 https://doi.org/10.3892/ol.2017.5997
Pages: 4533-4539

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pituitary adenoma (PA) is a common type of benign tumor of the pituitary gland that is characterized by specific signs and symptoms, primarily associated with hypersecretion of pituitary glycoprotein hormones (thyroid-stimulating, growth and adrenocorticotrophic hormones, and prolactin). Surgery is the first‑line treatment, although postoperative residual tissues/cells and subsequent recurrence remain notable complications. Gene therapy is an effective approach for treatment, as previous studies have demonstrated that the Notch signaling pathway participates in the pathogenesis of PA. The focus of the present study was on the associations between the expression of the Notch1 receptor and its ligands δ-like canonical Notch ligand (Dll) 1, Dll3 and Dll4 in patients with PA. Using reverse transcription-quantitative polymerase chain reaction and western blot analyses, to the best of our knowledge, this is the first study to provide a description of the differential expression of the Notch1 receptor and its ligands Dll1, Dll3, and Dll4 in various types of human PA at the mRNA and protein levels. The results of the present study demonstrated that Notch1 protein expression was positively correlated with Dll4 protein expression, but negatively correlated with Dll3 protein expression, indicating synergistic effects between the Notch1 receptor and Dll4 ligand. Furthermore, the Dll3 ligand may be an inhibitor of the Notch1 receptor, indicating an antagonistic association between Notch1 and the Dll3 ligand. These results have identified a potential target for the treatment of patients with PA.

View Figures

View References

1	Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML and McCutcheon IE: The prevalence of pituitary adenomas. Cancer. 101:613–619. 2004. View Article : Google Scholar : PubMed/NCBI
2	Ironside JW: Best Practice No 172: Pituitary gland pathology. J Clin Pathol. 56:561–568. 2003. View Article : Google Scholar : PubMed/NCBI
3	Scanarini M and Mingrino S: Functional classification of pituitary adenomas. Acta Neurochir (Wien). 52:195–202. 1980. View Article : Google Scholar : PubMed/NCBI
4	Korbonits M and Carlsen E: Recent clinical and pathophysiological advances in non-functioning pituitary adenomas. Horm Res. 71 Suppl 2:S123–S130. 2009.
5	Jaffe CA: Clinically non-functioning pituitary adenoma. Pituitary. 9:317–321. 2006. View Article : Google Scholar : PubMed/NCBI
6	Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA and Beckers A: High prevalence of pituitary adenomas: A cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 91:4769–4775. 2006. View Article : Google Scholar : PubMed/NCBI
7	Greenman Y and Stern N: Non-functioning pituitary adenomas. Best Pract Res Clin Endocrinol Metab. 23:625–638. 2009. View Article : Google Scholar : PubMed/NCBI
8	Zhan X and Desiderio DM: Signaling pathway networks mined from human pituitary adenoma proteomics data. BMC Med Genomics. 3:132010. View Article : Google Scholar : PubMed/NCBI
9	Indraccolo S, Minuzzo S, Masiero M and Amadori A: Ligand-driven activation of the notch pathway in T-ALL and solid tumors: Why Not(ch)? Cell Cycle. 9:80–85. 2010. View Article : Google Scholar : PubMed/NCBI
10	Melmed S: Pathogenesis of pituitary tumors. Nature Rev Endocrinol. 7:257–266. 2011. View Article : Google Scholar
11	Bianchi S, Dotti MT and Federico A: Physiology and pathology of notch signalling system. J Cell Physiol. 207:300–308. 2006. View Article : Google Scholar : PubMed/NCBI
12	Lai EC: Notch signaling: Control of cell communication and cell fate. Development. 131:965–973. 2004. View Article : Google Scholar : PubMed/NCBI
13	Artavanis-Tsakonas S, Rand MD and Lake RJ: Notch signaling: Cell fate control and signal integration in development. Science. 284:770–776. 1999. View Article : Google Scholar : PubMed/NCBI
14	Greenwald I: LIN-12/Notch signaling: Lessons from worms and flies. Genes Dev. 12:1751–1762. 1998. View Article : Google Scholar : PubMed/NCBI
15	Artavanis-Tsakonas S, Matsuno K and Fortini ME: Notch signaling. Science. 268:225–232. 1995. View Article : Google Scholar : PubMed/NCBI
16	Moreno CS, Evans CO, Zhan X, Okor M, Desiderio DM and Oyesiku NM: Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. Cancer Res. 65:10214–10222. 2005. View Article : Google Scholar : PubMed/NCBI
17	Miao Z, Miao Y, Lin Y and Lu X: Overexpression of the Notch3 receptor in non-functioning pituitary tumours. J Clin Neurosci. 19:107–110. 2012. View Article : Google Scholar : PubMed/NCBI
18	Lu R, Gao H, Wang H, Cao L, Bai J and Zhang Y: Overexpression of the Notch3 receptor and its ligand Jagged1 in human clinically non-functioning pituitary adenomas. Oncol Lett. 5:845–851. 2013.PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Wang Z, Li Y, Kong D and Sarkar FH: The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. Curr Drug Targets. 11:745–751. 2010. View Article : Google Scholar : PubMed/NCBI
21	Hu XB, Feng F, Wang YC, Wang L, He F, Dou GR, Liang L, Zhang HW, Liang YM and Han H: Blockade of Notch signaling in tumor-bearing mice may lead to tumor regression, progression, or metastasis, depending on tumor cell types. Neoplasia. 11:32–38. 2009. View Article : Google Scholar : PubMed/NCBI
22	Roy M, Pear WS and Aster JC: The multifaceted role of Notch in cancer. Curr Opin Genet Dev. 17:52–59. 2007. View Article : Google Scholar : PubMed/NCBI
23	Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, Zlobin A, Osborne BA, Gottipati S, Aster JC, Hahn WC, et al: Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med. 8:979–986. 2002. View Article : Google Scholar : PubMed/NCBI
24	Bao B, Wang Z, Ali S, Kong D, Li Y, Ahmad A, Banerjee S, Azmi AS, Miele L and Sarkar FH: Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett. 307:26–36. 2011. View Article : Google Scholar : PubMed/NCBI
25	Chen Y, de Marco MA, Graziani I, Gazdar AF, Strack PR, Miele L and Bocchetta M: Oxygen concentration determines the biological effects of Notch-1 signaling in adenocarcinoma of the lung. Cancer Res. 67:7954–7959. 2007. View Article : Google Scholar : PubMed/NCBI
26	Koch U and Radtke F: Notch and cancer: A double-edged sword. Cell Mol Life Sci. 64:2746–2762. 2007. View Article : Google Scholar : PubMed/NCBI
27	Gao J, Chen C, Hong L, Wang J, Du Y, Song J, Shao X, Zhang J, Han H, Liu J and Fan D: Expression of Jagged1 and its association with hepatitis B virus X protein in hepatocellular carcinoma. Biochem Biophys Res Commun. 356:341–347. 2007. View Article : Google Scholar : PubMed/NCBI
28	Purow BW, Haque RM, Noel MW, Su Q, Burdick MJ, Lee J, Sundaresan T, Pastorino S, Park JK, Mikolaenko I, et al: Expression of Notch-1 and its ligands, Delta-Like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res. 65:2353–2363. 2005. View Article : Google Scholar : PubMed/NCBI
29	Somasundaram K, Reddy SP, Vinnakota K, Britto R, Subbarayan M, Nambiar S, Hebbar A, Samuel C, Shetty M, Sreepathi HK, et al: Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma. Oncogene. 24:7073–7083. 2005. View Article : Google Scholar : PubMed/NCBI
30	Maemura K, Yoshikawa H, Yokoyama K, Ueno T, Kurose H, Uchiyama K and Otsuki Y: Delta-like 3 is silenced by methylation and induces apoptosis in human hepatocellular carcinoma. Int J Oncol. 42:817–822. 2013.PubMed/NCBI
31	Chapman G, Sparrow DB, Kremmer E and Dunwoodie SL: Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis. Hum Mol Genet. 20:905–916. 2011. View Article : Google Scholar : PubMed/NCBI
32	Loomes KM, Stevens SA, O'Brien ML, Gonzalez DM, Ryan MJ, Segalov M, Dormans NJ, Mimoto MS, Gibson JD, Sewell W, et al: Dll3 and Notch1 genetic interactions model axial segmental and craniofacial malformations of human birth defects. Dev Dyn. 236:2943–2951. 2007. View Article : Google Scholar : PubMed/NCBI
33	Patel NS, Li JL, Generali D, Poulsom R, Cranston DW and Harris AL: Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res. 65:8690–8697. 2005. View Article : Google Scholar : PubMed/NCBI
34	Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R and Ish-Horowicz D: Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation. 69:135–144. 2001. View Article : Google Scholar : PubMed/NCBI
35	Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, Biswas S, Turley H, Heikamp E, Hainfellner JA and Harris AL: Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res. 67:11244–11253. 2007. View Article : Google Scholar : PubMed/NCBI
36	Djokovic D, Trindade A, Gigante J, Badenes M, Silva L, Liu R, Li X, Gong M, Krasnoperov V, Gill PS and Duarte A: Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis. BMC Cancer. 10:6412010. View Article : Google Scholar : PubMed/NCBI
37	Al Haj, Zen A, Oikawa A, Bazan-Peregrino M, Meloni M, Emanueli C and Madeddu P: Inhibition of delta-like-4-mediated signaling impairs reparative angiogenesis after ischemia. Circ Res. 107:283–293. 2010. View Article : Google Scholar : PubMed/NCBI
38	Williams CK, Li JL, Murga M, Harris AL and Tosato G: Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood. 107:931–939. 2006. View Article : Google Scholar : PubMed/NCBI
39	Weng AP and Aster JC: Multiple niches for Notch in cancer: Context is everything. Curr Opin Genet Dev. 14:48–54. 2004. View Article : Google Scholar : PubMed/NCBI
40	Hellström M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N, et al: Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature. 445:776–780. 2007. View Article : Google Scholar : PubMed/NCBI
41	Bray SJ: Notch signalling: A simple pathway becomes complex. Nat Rev Mol Cell Biol. 7:678–689. 2006. View Article : Google Scholar : PubMed/NCBI
42	Ladi E, Nichols JT, Ge W, Miyamoto A, Yao C, Yang LT, Boulter J, Sun YE, Kintner C and Weinmaster G: The divergent DSL ligand Dll3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands. J Cell Biol. 170:983–992. 2005. View Article : Google Scholar : PubMed/NCBI